SlideServe
Télécharger Obtenir Pro
Menu
Accueil Pro
Préférences
ApparenceLight Aide et commentaires
© SlideServe · v2026

Presented By Joyce Liu at 2014 ASCO Annual Meeting

stasia avatar
stasia
17 diapositives · 339 Views · Jul 25, 2014

A Randomized Phase 2 Trial Comparing Efficacy of the Combination of the PARP-inhibitor Olaparib and the Anti-angiogenic Cediranib Against Olaparib Alone in Recurrent Platinum-sensitive Ovarian Cancer. Presented By Joyce Liu at 2014 ASCO Annual Meeting.

#presented by joyce liu at 2014 asco annual meeting #presented by joyce liu at 2014 asco annual meeting ppt #powerpoint #presentation
Presented By Joyce Liu at 2014 ASCO Annual Meeting - slide 1
01 / 17Presented By Joyce Liu at 2014 ASCO Annual Meeting
1 / 17

Télécharger la présentation

Presented By Joyce Liu at 2014 ASCO Annual Meeting
Une image / un lien ci-dessous est fourni (tel quel) pour télécharger la présentation

Politique de téléchargement : le contenu du site vous est fourni TEL QUEL pour votre information et votre usage personnel ; il ne peut être vendu, concédé sous licence ni partagé sur d’autres sites sans l’accord de son auteur.Le contenu vous est fourni TEL QUEL, pour votre information et votre usage personnel uniquement. Téléchargez la présentation en cliquant sur ce lien. Lors du téléchargement, si vous ne parvenez pas à télécharger une présentation, l’éditeur a peut-être supprimé le fichier de son serveur.Pendant le téléchargement, si vous ne parvenez pas à obtenir une présentation, le fichier a peut-être été supprimé par l’éditeur.

F I N

Plus de contenu associé

Transcription de la présentation

  1. A Randomized Phase 2 Trial Comparing Efficacy of the Combination of the PARP-inhibitor Olaparib and the Anti-angiogenic Cediranib Against Olaparib Alone in Recurrent Platinum-sensitive Ovarian Cancer Presented By Joyce Liu at 2014 ASCO Annual Meeting

  2. Background: cediranib and olaparib are active agents in ovarian cancer Presented By Joyce Liu at 2014 ASCO Annual Meeting

  3. Cediranib and olaparib have synergistic activity in vitro Presented By Joyce Liu at 2014 ASCO Annual Meeting

  4. Phase 1 study of cediranib and olaparib demonstrated activity in ovarian cancer patients Presented By Joyce Liu at 2014 ASCO Annual Meeting

  5. Study Objectives Presented By Joyce Liu at 2014 ASCO Annual Meeting

  6. Study Design Presented By Joyce Liu at 2014 ASCO Annual Meeting

  7. Key eligibility criteria Presented By Joyce Liu at 2014 ASCO Annual Meeting

  8. Statistical Considerations Presented By Joyce Liu at 2014 ASCO Annual Meeting

  9. Study Status and Data Analysis Presented By Joyce Liu at 2014 ASCO Annual Meeting

  10. Patient Characteristics Presented By Joyce Liu at 2014 ASCO Annual Meeting

  11. Primary Outcome: Cediranib/olaparib significantly increased PFS compared to olaparib alone Presented By Joyce Liu at 2014 ASCO Annual Meeting

  12. Secondary Outcome: Cediranib/olaparib significantly increased overall response rate (ORR) compared to olaparib alone Presented By Joyce Liu at 2014 ASCO Annual Meeting

  13. Cediranib/olaparib significantly increased PFS in patients without a BRCA mutation Presented By Joyce Liu at 2014 ASCO Annual Meeting

  14. Treatment-related Adverse Events Presented By Joyce Liu at 2014 ASCO Annual Meeting

  15. Tolerability of cediranib/olaparib combination Presented By Joyce Liu at 2014 ASCO Annual Meeting

  16. Conclusions Presented By Joyce Liu at 2014 ASCO Annual Meeting

  17. Acknowledgments Presented By Joyce Liu at 2014 ASCO Annual Meeting